PEStore

Buyout PE

CX Partners

CX Partners acquires controlling stakes in established, profitable businesses, from New Delhi, India. It states a focus on healthcare & life sciences, financial services, consumer & retail and software & internet.

Disclosed holdings
Earliest stated investment
HeadquartersNew Delhi, India
Largest single fundNot stated

Stated investment criteria

What CX Partners says it buys

Read from CX Partners’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.

OfficesDelhi1

A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. Nothing here is a commitment by CX Partners to consider any particular business, and nothing on this page is represented as being for sale.

Regulatory record

How CX Partners is registered

From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.

Adviser statusExempt reporting adviser
Regulatory assets under managementNot reported by an ERA
SEC adviser numberCRD 162587

An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.

Recorded transactions

Buying and selling

Deals in which CX Partners is named as buyer or seller in the transaction archive. 1 recorded exit, most recently in 2016.

CompanySideCounterpartyYearConsideration
The Minacs Group Pte Ltd.SoldTD SYNNEX2016$420m

Compiled from a transaction archive of 10,204 recorded deals. Most private transactions are never disclosed, so this is a sample of a firm’s activity rather than a complete record of it.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this CX Partners?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other buyout pe investors active in healthcare & life sciences.